La vendita allo scoperto per Hyliion Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Hyliion Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Hyliion Holdings (AMEX:HYLN) Azioni, Report sulle vendite allo scoperto

Hyliion Holdings

Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

Envoy Medical, Inc. - Class A Common Stock

COCH

HYLN

SXTP

Scopri le penny stock sotto i $5 in cui Hyliion e altri due titoli stanno attirando l&#39;attenzione degli insider.

Penny stock sotto i $5: Hyliion e altri 2 titoli sotto osservazione

Hyliion Holdings Corp. Class A Common Stock

Hyliion Holdings Corp

Monolithic Power Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NYSE">MPWR</a>) short percent of float has fallen 11.58% since its last report. The company recently reported that it has 2.30 million shares sold short, which is 6.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Monolithic Power Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744203624_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monolithic Power Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Monolithic Power Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Monolithic Power Systems's peer group average for short interest as a percentage of float is 5.17%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

MPWR

Is the Market Bullish or Bearish on Monolithic Power Systems?

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Evolus, presenting an average target of $24.25, a high estimate of $27.00, and a low estimate of $22.00. This current average has increased by 2.67% from the previous average price target of $23.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1744203621_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $25.00&#x7C;$22.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $22.00&#x7C;$20.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $22.00&#x7C;$22.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Evolus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evolus compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Evolus's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Evolus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EOLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evolus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Evolus Better</h2>
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
<h3>Evolus's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Evolus showcased positive performance, achieving a revenue growth rate of 29.42% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Evolus's net margin excels beyond industry benchmarks, reaching -8.6%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -119.02%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Evolus's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.94%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Evolus's debt-to-equity ratio surpasses industry norms, standing at 23.54. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

EOLS

Breaking Down Evolus: 8 Analysts Share Their Views

Ross Stores's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NYSE">ROST</a>) short percent of float has fallen 8.93% since its last report. The company recently reported that it has 4.94 million shares sold short, which is 1.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ross Stores Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744203618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ross Stores has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ross Stores's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ross Stores's peer group average for short interest as a percentage of float is 13.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ROST

How Do Investors Really Feel About Ross Stores?

8 analysts have expressed a variety of opinions on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Humana, presenting an average target of $280.38, a high estimate of $316.00, and a low estimate of $255.00. This upward trend is evident, with the current average reflecting a 1.31% increase from the previous average price target of $276.75.
<img src="https://www.benzinga.com/files/images/story/2025/1744203611_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $316.00&#x7C;$305.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $256.00&#x7C;$257.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $270.00&#x7C;$255.00 &#x7C; 
&#x7C;Ben Hendrix &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $283.00&#x7C;$283.00 &#x7C; 
&#x7C;Sarah James &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Neutral &#x7C; $290.00&#x7C;$290.00 &#x7C; 
&#x7C;Erin Wright &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $285.00&#x7C;$301.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $255.00&#x7C;$253.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $288.00&#x7C;$270.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Humana. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Humana's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Humana's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Humana analyst ratings.</a>
<h2>Delving into Humana's Background</h2>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Key Indicators: Humana's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Humana showcased positive performance, achieving a revenue growth rate of 10.4% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Humana's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.37%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Humana's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -4.08%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Humana's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.44%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Humana's debt-to-equity ratio is below the industry average. With a ratio of 0.72, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About Humana

Biotech

General

OGEN

Oragenics Submits Clinical Trial Protocol To Health and Disability Ethics Committee in New Zealand For Phase IIa Concussion Trial

UBS analyst Arpine Kocharyan initiates coverage on Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Buy rating and announces Price Target of $49.

Price Target

Initiation

UBS Initiates Coverage On Six Flags Entertainment with Buy Rating, Announces Price Target of $49

Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares are trading<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> higher in the premarket session on Wednesday.</a>
On Wednesday, the company raised 2025 pro forma revenue by 30% to <a href="https://www.benzinga.com/pressreleases/25/04/ac44707820/interactive-strength-inc-nasdaq-trnr-increases-guidance-by-30-to-more-than-65m-in-2025-pro-forma-" target="_blank" rel="noreferrer noopener">more than $65 million.</a>
The company <a href="https://interactivestrength.com/investor-presentation-april-2025/" target="_blank" rel="noreferrer noopener">highlighted </a>that its recently announced binding agreement to acquire Wattbike has sold more than 100,000 bikes. Wattbike is a UK-based indoor cycling brand.
Wattbike has fully met its FY26 earnout target with $26 million in revenue, surpassing the $22 million minimum revenue required to begin the payout.
The company says Wattbike&#8217;s earnout will be fully achieved if revenue exceeds $29 million in FY27, with a minimum threshold of $25 million to trigger the earnout.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44166759/interactive-strength-targets-global-wellness-market-with-15-million-revenue-boost-from-acquisition" rel="noreferrer noopener"> Interactive Strength Targets Global Wellness Market with $15 Million Revenue Boost from Acquisition</a>
The company signed a binding <a href="https://www.benzinga.com/news/25/04/44685029/whats-going-on-with-interactive-strength-trnr-stock" target="_blank" rel="noreferrer noopener">agreement to acquire </a><a href="https://www.benzinga.com/news/25/04/44685029/whats-going-on-with-interactive-strength-trnr-stock" target="_blank" rel="noreferrer noopener">Wattbike</a> on Tuesday.
Interactive Strength said the acquisition is expected to close in the second quarter and be immediately accretive.
Wattbike&#8217;s CEO, Stephen Loftus, highlighted the opportunity for accelerated global growth, supported by Interactive Strength&#8217;s sales and marketing scale.
Interactive Strength also plans to integrate Wattbike with its Taiwan-based supply team and upcoming Sportstech acquisition, positioning the company as a uniquely diversified leader in global fitness.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, TRNR stock has lost over 99% in the past year.
Price Action: TRNR shares are trading higher by 3.25% to $0.9316&nbsp;premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44708618/china-retaliates-with-massive-84-tariff-hike-on-us-goods-amid-escalating-trade-war" target="_blank" rel="noreferrer noopener">Xi Jinping Hits Back: China Raises Tariffs On US Goods To 84%, Doubling Down On Trade War</a></li>
</ul>
Photo: Shutterstock

Equities

Movers

TRNR

What's Going On With Interactive Strength Stock Today?

Scotiabank analyst Nicholas Yulico upgrades Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) from Sector Perform to Sector Outperform and lowers the price target from $333 to $305.

Upgrades

Scotiabank Upgrades Public Storage to Sector Outperform, Lowers Price Target to $305

The 10 wealthiest individuals in the world, including&nbsp;Elon Musk, CEO of&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), have lost $174 billion following President Donald Trump&#8216;s tariff announcement on April 2. On a year-to-date basis, they lost nearly a staggering $350 billion.
What Happened: Following Trump&#8217;s tariff declaration last Wednesday, the S&amp;P 500 plummeted 11%. This resulted in a significant shrinkage of the equity stakes of the world&#8217;s richest, who had a combined net worth exceeding&nbsp;$2 trillion at the start&nbsp;of 2025. 
As per the Bloomberg Billionaires Index, since the tariff announcement on April 2, Elon Musk and Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg saw the maximum decline, with Musk losing $33 billion, while Zuckerberg lost $26 billion. Amazon&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Jeff Bezos saw a decline of $21 billion, while Oracle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NASDAQ">ORCL</a>) CEO Larry Ellison witnessed a $20 billion drop in their net worth.
Google (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) founders, Larry Page and Sergey Brin, lost $12 billion and $11 billion, each. Former Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) CEOs Bill Gates and Steve Balmer saw their fortune decline by $15 billion and $9 billion, respectively.
Meanwhile, Bernard Arnault, the French billionaire and CEO of the luxury brand LVMH, lost $14 billion of his net worth.
Surprisingly, legendary investor and chief of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), Warren Buffett&#8217;s net worth also fell by $13 billion since Trump&#8217;s tariff announcement on April 2. However, Buffett maintained a positive net worth year-to-date.
Why It Matters: On Monday, Musk&#8217;s <a href="https://www.benzinga.com/markets/25/04/44700935/elon-musks-net-worth-dives-below-300-billion-for-the-first-time-since-november-amid-tesla-attacks-an">net worth dipped </a>below $300 billion, a level unseen since the previous year. The Bloomberg Billionaires Index indicated that Musk&#8217;s wealth was $298 billion at Monday&#8217;s market close, marking a reduction of nearly $135 billion, or 31%, since the beginning of the year.
Meanwhile, President Trump&#8217;s <a href="https://www.benzinga.com/markets/25/04/44706255/trump-loses-500-million-in-personal-wealth-as-his-own-tariff-policy-sparks-sharp-declines-across-his-business-empire">net worth </a>also took a significant hit post the implementation of his extensive new tariffs. Within days, Trump's estimated net worth declined by nearly $600 million, falling from $4.7 billion to $4.1 billion, as per Forbes&#8217; analysis.
President Trump&#8217;s sweeping tariffs, announced on April 2, sparked market turmoil. The next day, stocks endured their worst single-day decline in five years, with the S&amp;P 500 falling nearly 5%, the Dow dropping 1,679 points, and the Nasdaq plummeting 6%.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/trading-ideas/long-ideas/25/04/44697177/marjorie-taylor-greene-buys-the-dip-congresswoman-purchases-shares-of-apple-amazon-nike-" target="_blank" rel="noreferrer noopener">Marjorie Taylor Greene Buys The Dip: Congresswoman Purchases Shares Of Apple, Amazon, Nike And More Following Tariff-Related Sell-Off</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AMZN

GOOG

GOOGL

MSFT

ORCL

TSLA

Trump's Tariff Turmoil Topples Ultra-Rich's Wealth — $174B Wiped Out From Fortunes Of World's Top 10 Billionaires, Including Elon Musk, Warren Buffett And Mark Zuckerberg

Tempest Therapeutics, Inc. - Common Stock

TPST

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) shares are trading higher premarket after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44707201/delta-air-lines-announces-march-quarter-2025-financial-results" rel="noreferrer noopener">first-quarter 2025 results</a>.
Delta reported fourth-quarter operating revenue growth of 2% year-over-year to $14.04 billion, beating the consensus of $13.02 billion. Adjusted operating revenue was $12.98 billion (+3.3% YoY)
The adjusted average fuel price was $2.47 per gallon, down from $2.79 in last year&#8217;s quarter. Adjusted EPS was $0.46 (+2% YoY), beating the consensus of $0.38.
Related: <a target="_blank" href="https://www.benzinga.com/25/04/44705362/top-wall-street-forecasters-revamp-delta-air-lines-price-expectations-ahead-of-q1-earnings" rel="noreferrer noopener">Top Wall Street Forecasters Revamp Delta Air Lines Price Expectations Ahead Of Q1 Earnings</a>
Total passenger revenue for the quarter grew 3% year over year to $11.48 billion; cargo revenue grew 17% year over year to $208 million, and Other revenue was $2.352 billion (-4% year over year).
Delta recorded an adjusted operating income of $591 million, down from $640 million YoY, with an adjusted operating margin of 4.6%, down 50 bps.
Adjusted operating expenses increased by 4% YoY to $12.388 billion, and Adjusted Non-fuel costs were $9.875 billion (+7% YoY) for the quarter.
Delta generated an adjusted operating cash flow of $2.44 billion (-1% Y/Y) in the March quarter, and free cash flow stood at $1.28 billion.
As of the March quarter, Delta reported adjusted net debt of $16.9 billion, down $1.1 billion from year-end 2024. Total liquidity was $6.8 billion, including $3.1 billion in undrawn revolver capacity.
The passenger load factor dropped 81.4% from 82.7% last year. DAL&#8217;s Air Traffic Liability ended the quarter at $10 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/travel/25/04/44671680/which-us-airline-is-facing-the-strongest-industry-tailwinds" rel="noreferrer noopener">Which US Airline Faces The Strongest Industry Tailwinds?</a>
Delta&#8217;s Chief Financial Officer, Dan Janki, noted that the company delivered better-than-expected results despite early-year weather challenges. &#8220;Our teams ran a strong operation… enabling us to drive efficiency and deliver non-fuel unit cost growth of up 2.6 percent over prior year,&#8221; he said. Janki added that as Delta reduces capacity growth, it is &#8220;taking incremental action to manage costs,&#8221; and expects non-fuel unit cost growth to align with its long-term target of low-single-digit increases in the second quarter and beyond.
&#8220;With broad economic uncertainty around global trade, growth has largely stalled.&nbsp;In this slower-growth environment, we are protecting margins and cash flow by focusing on what we can control.&nbsp;This includes reducing planned capacity growth in the second half of the year to flat over last year while actively managing costs and capital expenditures,&#8221; commented Ed Bastian, Delta&#8217;s chief executive officer.
&#8220;We expect June quarter profitability of $1.5 to $2 billion.&nbsp;Given the lack of economic clarity, it is premature at this time to provide an updated full-year outlook.&nbsp;Given our position of strength, our bias toward action, and the decline in fuel prices, Delta remains well positioned to deliver solid profitability and free cash flow for the year. I expect that our financial results will continue to lead the industry and validate our strategy to create differentiation and greater financial durability,&#8221; added Bastian.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634938/airline-earnings-at-risk-as-demand-dips-amid-weak-business-travel-low-transborder-traffic-doge-cuts-analyst-says" rel="noreferrer noopener">Airline Earnings At Risk As Demand Dips Amid Weak Business Travel, Low Transborder Traffic, DOGE Cuts: Analyst Says</a>
Second Quarter 2025 Outlook: DAL&#8217;s total revenue is expected to be down 2% to up 2% over the prior year, with an operating margin of 11%—14%.
Adjusted Earnings per share are forecasted between $1.70 and $2.30 versus the $2.39 estimate.
Delta is not reaffirming its full-year 2025 financial guidance and plans to provide an update later in the year as market visibility improves.
Price Action: DAL shares are trading lower by 0.45% at $35.73 premarket at the last check on Wednesday.
Image via Shutterstock

Earnings

Guidance

Delta Air Lines Wants To Protect Margins And Cash Flow Citing Economic Uncertainty, Does Not Reaffirm FY25 Outlook

RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) reported worse-than-expected third-quarter financial results on Tuesday.
Sales declined 3% year over year to $1.48 billion, missing the consensus of $1.51 billion. Adjusted EPS was 35 cents, missing the consensus of 49 cents.
Frank C. Sullivan, RPM chairman and CEO said, "Unseasonably cold weather in the southern U.S. and wildfires in the west reduced demand in geographies that typically have more construction and outdoor project activity in winter months."
"As we look toward the fourth quarter, macroeconomic conditions are challenging, but we are seeing pockets of positive momentum and are leveraging our focus on repair and maintenance in both construction and consumer end markets. As demonstrated in prior economic cycles, the ability of our products and services to extend asset life becomes even more attractive to end users when budgets are tight."
For the fourth quarter, RPM expects consolidated sales to remain flat compared to prior-year records.
RPM shares dipped 9.1% to close at $96.97 on Tuesday.
These analysts made changes to their price targets on RPM International following earnings announcement.
<ul>
<li>Baird analyst Ghansham Panjabi maintained RPM Intl with a Neutral and lowered the price target from $125 to $110.</li>
<li>BMO Capital analyst John McNulty maintained the stock with an Outperform rating and lowered the price target from $154 to $126.</li>
<li>Morgan Stanley analyst Vincent Sinisi maintained RPM with an Equal-Weight rating and cut the price target from $125 to $113.</li>
</ul>
Considering buying RPM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09085126/image-54-1024x590.png" alt="" class="wp-image-863776" style="width:522px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09085126/image-54-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09085126/image-54-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09085126/image-54-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09085126/image-54.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a> </li>
</ul>
Photo via Shutterstock

RPM International Analysts Slash Their Forecasts After Downbeat Earnings

BMO Capital analyst Andrew Strelzik maintains Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) with a Outperform and lowers the price target from $47 to $30.

PLAY

BMO Capital Maintains Outperform on Dave & Buster's Enter, Lowers Price Target to $30

Scotiabank analyst Ben Isaacson upgrades CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) from Sector Underperform to Sector Perform and maintains the price target from $81 to $81.

Scotiabank Upgrades CF Industries Holdings to Sector Perform, Maintains Price Target to $81

Global fintech firm Broadridge Financial Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) <a href="https://www.benzinga.com/pressreleases/25/04/n44704954/broadridge-collaborates-with-fnality-to-enable-real-time-settlement-for-intraday-repo-transactions">revealed it has concluded a successful joint effort</a> with blockchain payments company Fnality. 
The collaboration proved that Broadridge's Distributed Ledger Repo (DLR) platform can operate with Fnality's Payment System (FnPS), highlighting how tokenized assets can transform transaction processes in global financial markets.
Fnality is building a network of regulated wholesale payment systems powered by distributed ledger technology, each overseen by its local central bank. 
These systems, called Fnality Payment Systems (FnPS), allow participants to use digital versions of central bank funds for instant transactions. 
The partnership sets the stage for instant intraday repo settlements by utilizing tokenized money backed by central bank reserves.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44703031/this-beverage-maker-tobacco-company-and-packaged-food-giant-outshine-in-a-recession">This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession</a>
The combined use of Broadridge's DLR platform and Fnality's FnPS network illustrates how real-time delivery versus payment (DvP) can be achieved in repo markets. 
Leveraging tokenized funds tied to central bank reserves as the settlement foundation, the approach offers enhanced transaction speed and security. 
This development meets a critical industry demand for better liquidity management and lower risk in both the U.S. and European financial systems.
With planned rollouts in major markets, FnPS aims to support 24/7 cross-currency payments and atomic settlement, offering secure, institutional-grade digital cash for emerging digital asset markets.
Broadridge views this milestone as a major step toward broadening its digital footprint across Europe. The company aims to grow its DLR client base by offering near-instant settlement solutions to meet the increasing demand for speed and security in financial markets.
For its part, Fnality plans to extend its regulated blockchain-based wholesale payments infrastructure beyond the UK, targeting the U.S. as a critical expansion region.
Broadridge&#8217;s second-quarter 2025 sales grew <a href="https://www.benzinga.com/25/01/43394380/broadridge-financial-q2-beats-estimates-reaffirms-outlook">13.1% year-on-year to $1.589 billion</a>.
Broadridge provides technology solutions that support investing, corporate governance, and financial communications. Its platforms facilitate daily trades exceeding $10 trillion in securities and connect public companies with investors worldwide.
Price Action: BR shares closed lower by 1.32% at $217.22 on Tuesday.
Read Next: <a href="https://www.benzinga.com/tech/25/04/44695622/amazon-touts-ai-milestone-says-new-model-outshines-gpt-4o-in-real-time-speech">Amazon Touts AI Milestone, Says New Model Outshines GPT-4o In Real-Time Speech</a>
Photo: Shutterstock

Broadridge And Fnality Unlock Blockchain-Based Repo Settlements

Neogen Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) reported third-quarter 2025 adjusted EPS of 10 cents on Wednesday, down from 12 cents a year ago, missing the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 11 cents</a>.
The company reported sales of $220.98 million, down 3.4% year over year, missing the consensus of $224.88 million.
Core revenue, which excludes the impacts of foreign currency translation and acquisitions completed and product lines discontinued in the last 12 months, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44707568/neogen-announces-third-quarter-2025-results" rel="noreferrer noopener">increased by 0.2%</a>.
Acquisitions and discontinued product lines had a negative impact of 0.5% while foreign currency had a negative impact of 3.1%.
The gross margin was 49.9% down from 51.1% a year ago, mainly due to lower revenue and higher integration costs. Excluding integration and restructuring costs, gross margin was 51.5% in the third quarter compared to 51.8% in the prior-year quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44698463/cartesian-therapeutics-reports-strong-12-month-data-for-lead-cell-therapy-in-myasthenia-gravis-patients" rel="noreferrer noopener">Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients</a>
Third-quarter Adjusted EBITDA was $48.5 million, representing an adjusted EBITDA margin of 22%, compared with $52.7 million and a margin of 23% a year earlier.
Revenues for the Food Safety segment were $152.7 million, a decrease of 3.2%, consisting of 1.5% core growth, a negative 0.3% impact from discontinued product lines, and a negative foreign currency impact of 4.4%.
<ul>
<li>Core growth was driven largely by biosecurity and bacterial and general sanitation product categories, which benefited from strong growth in pathogen detection products.</li>
</ul>
Revenues for the Animal Safety segment were $68.2 million, a decrease of 4%, consisting of a 2.6% core revenue decline, an unfavorable 0.4% foreign currency impact and a negative 1% impact from discontinued product lines.
<ul>
<li>Growth was led by the animal care and other and biosecurity product categories, particularly in small-animal supplements, rodent control, and cleaner and disinfectant products, and offset by a decline in the vet instruments product category.</li>
</ul>
The company&#8217;s Genomics business experienced a core revenue decline in the mid-single-digit range. Increased sales into bovine markets were offset by declines in other areas, consistent with the focused restructuring activities executed in the second quarter.
Guidance: The company is updating its full-year outlook, primarily due to lower-than-expected third-quarter results, the rising level of macroeconomic uncertainty affecting the company&#8217;s end markets, and the expected impact of tariffs in the fourth quarter.
Neogen expects fiscal year 2025 sales of approximately $895 million, down from prior guidance of $905 million-$925 million and consensus of $910.23 million.
The company forecasts 2025 adjusted EBITDA of approximately $195 million compared to prior guidance of $205 million-$215 million.
Management Update: Neogen CEO John Adent will be stepping down after eight years the company. Adent will continue to serve in his existing roles until his successor <a href="https://www.benzinga.com/pressreleases/25/04/b44707614/neogen-announces-ceo-transition" target="_blank" rel="noreferrer noopener">has been appointed</a>.
Price Action: NEOG stock is down 17.6% at $5.80 during the premarket session at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44698379/argenxs-flagship-drug-vyvgart-shows-sustained-disease-control-in-rare-neuromuscular-disease-patients" target="_blank" rel="noreferrer noopener">Argenx&#8217;s Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients</a></li>
</ul>
Photo: Shutterstock/MacroEcon

Health Care

Management

NEOG

Neogen Q3 Earnings Fall Short On Expectations, Cuts Guidance Amid Macro Headwinds And Tariff Concerns

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays cut Americold Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) price target from $26 to $21. Barclays analyst Anthony Powell upgraded the stock from Equal-Weight to Overweight. Americold Realty Trust shares closed at $17.50 on Tuesday. <a href="https://www.benzinga.com/quote/COLD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan slashed the price target for PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) from $210 to $160. JP Morgan analyst Alexei Gogolev downgraded the stock from Overweight to Neutral. PTC shares closed at $136.74 on Tuesday. <a href="https://www.benzinga.com/quote/PTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies lowered Xenia Hotels &amp; Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) price target from $18 to $10. Jefferies analyst David Katz downgraded the stock from Buy to Hold. Xenia Hotels shares closed at $9.22 on Tuesday. <a href="https://www.benzinga.com/quote/XHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Goosehead Insurance, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) from $132 to $122. Piper Sandler analyst Paul Newsome maintained an Overweight rating. Goosehead Insurance shares closed at $103.90 on Tuesday. <a href="https://www.benzinga.com/quote/GSHD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer cut the price target for Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) from $24 to $19. Oppenheimer analyst Brian Schwartz maintained an Outperform rating. Freshworks shares closed at $12.08 on Tuesday. <a href="https://www.benzinga.com/quote/FRSH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) price target from $600 to $650. Mizuho analyst Ann Hynes maintained an Outperform rating. UnitedHealth shares settled at $553.08 on Tuesday. <a href="https://www.benzinga.com/quote/UNH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) price target from $17 to $16. Morgan Stanley analyst Alex Straton maintained an Equal-Weight rating. Levi Strauss shares closed at $12.42 on Tuesday. <a href="https://www.benzinga.com/quote/LEVI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho slashed Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $285 to $255. Mizuho analyst James Lee maintained an Outperform rating. Amazon shares closed at $170.66 on Tuesday.  <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital cut the price target for RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) from $154 to $126. BMO Capital analyst John McNulty maintained an Outperform rating. RPM shares settled at $96.97 on Tuesday. <a href="https://www.benzinga.com/quote/RPM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) price target from $157 to $172. Goldman Sachs analyst Asad Haider upgraded the stock from Neutral to Buy. Johnson &amp; Johnson shares closed at $150.00 on Tuesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AMZN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53-1024x584.png" alt="" class="wp-image-863746" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09084430/image-53.png 1080w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

COLD

FRSH

GSHD

LEVI

Amazon.com To $255? Here Are 10 Top Analyst Forecasts For Wednesday

Subcutaneous DARZALEX&reg; is co-formulated with Halozyme&#39;s ENHANZE&reg; drug delivery technology

HALO

Halozyme Therapeutics Announces European Commission Approved Subcutaneous DARZALEX-Based Quadruplet Regimen For Treatment Of Patients With Newly Diagnosed Multiple Myeloma, Regardless Of Transplant Eligibility

Needham analyst Serge Belanger reiterates Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) with a Buy and maintains $46 price target.

Reiteration

COLL

Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $46 Price Target

OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) reported quarterly losses of $(1.17) per share. This is a 178.57 percent decrease over losses of $(0.42) per share from the same period last year. The company reported $5.78 million in sales this quarter. This is a 0.46 percent decrease over sales of $5.81 million the same period last year.

Comments

Hyliion Holdings

Vendite allo scoperto

Hyliion Holdings (AMEX:HYLN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO